Sky Kreuzberg sits 4 % below the marketplace baseline — a value-leaning posture typical for a Kreuzberg metro pharmacy.
Lifting realised €/g by €0,30 — through deeper medium-tier coverage and toolkit-led substitution — unlocks an estimated €9 558 / period of incremental gross margin without raising any individual price.
| Out-of-stock SKU | Substituted with | Match score | Margin held |
|---|---|---|---|
| Cannamedical Sativa forte NM WT €8,86 / g |
AVAAY Signature 28/1 WB €8,94 / g |
91 / 100 | +€5,00 / g |
| Pedanios 26/1 EHD-CA €5,93 / g |
Cannamedical Sativa Classic NM GD €8,53 / g |
86 / 100 | +€2,60 / g |
| Demecan 22/1 RKA €7,12 / g |
Avaay Khalifa 28/1 KM €9,24 / g |
88 / 100 | +€2,12 / g |
The opportunity: profile-match rate climbing from 64 % to 80 % at Sky Kreuzberg's current volume preserves an estimated +€1 950 / period in gross margin, without any change in shelf pricing.
| Manufacturer | Est. share of Sky sales | Marketplace avg €/g | Coverage |
|---|---|---|---|
| Cansativa | 22 % | €4,69 | 192 / 264 pharmacies |
| Four 20 Pharma | 15 % | €5,55 | 264 / 264 pharmacies |
| Remexian Pharma | 12 % | €4,26 | 199 / 264 pharmacies |
| enua | 10 % | €5,38 | 246 / 264 pharmacies |
| Demecan | 8 % | €6,72 | 250 / 264 pharmacies |
Sky Kreuzberg's top-5 leans value (Cansativa, Remexian) and mid (Four 20, enua). The medium-tier deepening opportunity sits with Demecan (€6,72/g) and unrepresented partners like Cantourage (€6,62/g) and Iuvo (€7,79/g).
Closes the €6,50–7,50/g coverage gap. Expected uplift €0,12/g group avg.
Unlocks the premium-tier patient who currently leaves Berlin to source it.
Anchors the €8+ price band; pairs with toolkit-led profile-match substitution.
Already stocked. Currently 8 % of basket; benchmark partner pharmacies sit at 12–14 %.
Not stocked. €6,62/g avg, 190 partner pharmacies — a notable gap for a Berlin metro store.
Activate the Brand-Integrity Toolkit's substitution console and compliance scripts. Modeled gross-margin uplift: +€1 950 / period.